1. Background {#sec210447}
=============

The resistance of major gram-negative bacteria, such as *Escherichia coli* and *Klebsiella*, against antibiotics of the beta-lactam group, especially carbapenem, is increasing. These bacteria isolated from infections in hospitals all over the world result in the failure of treatment ([@A33990R1]).

The combined use of aminoglycoside and beta-lactam group antibiotics increases permeability by chelation of bacterial cell walls. However, a high level of resistance against aminoglycoside is evident in strains that are resistant to beta-lactam group antibiotics ([@A33990R2], [@A33990R3]). This high resistance needs to be investigated in detail, and the molecular mechanisms and epidemiological features of aminoglycoside resistance should be the focus. According to molecular studies conducted to determine the resistance mechanisms in bacteria against aminoglycoside, the following three mechanisms are responsible for the resistance: enzymes that modify aminoglycoside, mutation in genes that transport aminoglycoside, and alteration in ribosomal target proteins ([@A33990R4]). A new resistance mechanism was discovered in 2003. This mechanism suggests that 16S rRNA methyltransferase genes are transported with plasmids and leads to a high level of resistance to aminoglycoside. This mechanism was demonstrated in *Pseudomonas aeruginosa* isolates in Japan and in *Enterobacteriaceae* isolates in France ([@A33990R5], [@A33990R6]). 16S rRNA methyltransferase was reported to significantly increase the level of aminoglycoside resistance by methylation of the G1405 residue (minimum inhibitory concentration \[MIC\] is typically ≥ 256 µg/mL) ([@A33990R7]).

16S rRNA methyltransferase enzymes are generally seen together with carbapenemases and extended-spectrum beta-lactamase (ESBL). The existence of 16S rRNA methyltransferase has been observed in isolates carrying the genes bla~*NDM-1*~, *bla*~*KPC-2*~, *bla*~*VEB*~, *bla*~*TEM*~, *bla*~*CTX-M*~, *bla*~*SHV*~, and *bla*~*OXA*~. This outcome can be attributed to beta-lactamase and methyltransferase enzymes being located on the same plasmid ([@A33990R8]-[@A33990R11]).

2. Objectives {#sec210448}
=============

This study aimed to detect the co-existence of 16S rRNA methyltransferase enzymes and beta-lactamase genes in multidrug resistant (MDR) *Klebsiella pneumoniae* strains isolated from clinical samples in healthcare-associated infections.

3. Methods {#sec210449}
==========

A total of 228 clinical samples (i.e., blood, urine, bronchoalveolar lavage, sputum, and surgical wound) were collected from different clinics of the Medical Faculty of Balcali hospital at Cukurova University, Turkey, between August and December 2014. All the laboratory tests were performed at the laboratory of the Center and Medical microbiology department of the university. The samples were cultured on blood agar and Endo agar plates (Merck, Germany) at 37°C for 24 hours. The isolates were first evaluated by Gram staining to examine the morphology of colonies and biochemical test characteristics. Then, the bacterial species were identified using the VITEK-2 automated identification system (Biomerieux, Basingstoke, UK).

The resistance of beta-lactam antibiotics was investigated by the Kirby-Bauer disk diffusion (KBDD) test. The presence of ESBL was verified by the double disc synergy test, and carbapenem resistance was determined using the modified Hodge test. *Escherichia coli* ATCC 25922 was used as the control culture. To detect aminoglycoside resistance, amikacin (30 µg) and gentamicin (10 µg) sensitivities were examined through the KBDD test. Minimum inhibitory concentrations were determined by the agar dilution method on Mueller-Hinton agar plates according to the protocol recommended by the European committee on antimicrobial susceptibility testing ([@A33990R12]).

In all isolates, DNA extraction was performed mechanically with a Mickle cell disruptor (The Mickle Lab. Engineering Co. Ltd., Gamshall, Surrey, UK). However, polymerase chain reaction (PCR) was performed only in isolates with an MIC value of \> 512 μg/mL for amikacin and \> 128 μg/mL for gentamicin to detect beta-lactamase genes and 16s rRNA methyltransferase genes. The multiplex PCR method was used to determine the presence of *armA*, *npmA*, *rmtA*, *rmtB*, *rmtC*, *rmtD*, *rmtE*, *rmtF*, *rmtG*, and *rmtH* genes ([@A33990R13]). In addition, a type-specific multiplex PCR protocol was used to determine the carbapenemase and ESBL genes ([Table 1](#tbl53067){ref-type="table"}) ([@A33990R14]-[@A33990R16]). The PCR products were separated on 1.5% agarose gel and monitored using a Kodak UV transilluminator (Kodak, New York, USA). A sequence analysis was performed using the dye terminator cycle sequencing method and the ABI Prism Big dye terminator kit (Applied Biosystems, Foster City, USA). The assay was conducted according to the manufacturer's standard protocol. Data were collected on an ABI 310 automated fluorescence sequencer (Applied Biosystems). The types of 16S rRNA methyltransferase, carbapenemase, and ESBL genes were identified by comparing them with sequences from the GenBank database (http://blast.ncbi.nlm.nih.gov/Blast.cgi). In all PCR procedures, distilled sterile water was used as the negative control. As no reference strains carrying *rmtC* were available, a positive control could not be used. Nevertheless, the sequences were verified by the DNA sequencing method.

###### PCR Primers Used in the Study ([@A33990R13], [@A33990R14], [@A33990R16])

  Multiplex Primers                        Gene                            Forward/Reverse                 Sequences (5'-3')         Product Size
  ---------------------------------------- ------------------------------- ------------------------------- ------------------------- --------------
  **TEM, SHV and OXA-1-like**              TEM                             F                               CATTTCCGTGTCGCCCTTATTC    800 bp
  R                                        CGTTCATCCATAGTTGCCTGAC                                                                    
  SHV                                      F                               AGCCGCTTGAGCAAATTAAAC           713 bp                    
  R                                        ATCCCGCAGATAAATCACCAC                                                                     
  OXA-1 like                               F                               GGCACCAGATTCAACTTTCAAG          564 bp                    
  R                                        GACCCCAAGTTTCCTGTAAGTG                                                                    
  **CTX-M group 1, group 2 and group 9**   CTX-M group 1                   F                               TTAGGAARTGTGCCGCTGYAb     688 bp
  R                                        CGATATCGTTGGTGGTRCCATb                                                                    
  CTX-M group 2                            F                               CGTTAACGGCACGATGAC              404 bp                    
  R                                        CGATATCGTTGGTGGTRCCATb                                                                    
  CTX-M group 9                            F                               TCAAGCCTGCCGATCTGGT             561 bp                    
  R                                        TGATTCTCGCCGCTGAAG                                                                        
  **CTX-M group 8/25**                     CTX-M-8, 25,26,39,40,41         F                               AACRCRCAGACGCTCTACb       326 bp
  R                                        TCGAGCCGGAASGTGTYATb                                                                      
  **VEB, PER and GES**                     GES                             F                               AGTCGGCTAGACCGGAAAG       399 bp
  R                                        TTTGTCCGTGCTCAGGAT                                                                        
  PER                                      F                               GCTCCGATAATGAAAGCGT             520 bp                    
  R                                        TTCGGCTTGACTCGGCTGA                                                                       
  VEB                                      F                               CATTTCCCGATGCAAAGCGT            648 bp                    
  R                                        CGAAGTTTCTTTGGACTCTG                                                                      
  **SME,IMI**                              SME                             F                               GAGGAAGACTTTGATGGGAGGAT   334 bp
  R                                        TCCCCTCAGGACCGCCAAG                                                                       
  IMI                                      F                               GGTGTCTACGCTTTAGACACTGGCTC      536 bp                    
  R                                        GCACGAATACGCGCTGCACCGG                                                                    
  **OXA-48-like**                          OXA-48-like                     F                               GCTTGATCGCCCTCGATT        281 bp
  R                                        GATTTGCTCCGTGGCCGAAA                                                                      
  **IMP, VIM and KPC**                     IMP                             F                               TTGACACTCCATTTACDGb       139 bp
  R                                        GATYGAGAATTAAGCCACYCTb                                                                    
  VIM                                      F                               GATGGTGTTTGGTCGCATA             390 bp                    
  R                                        CGAATGCGCAGCACCAG                                                                         
  KPC                                      F                               CATTCAAGGGCTTTCTTGCTGC          538 bp                    
  R                                        ACGACGGCATAGTCATTTGC                                                                      
  **GIM-1,SIM-1, NDM-1 and SPM-1**         GIM                             F                               CGTTGCCAGCTTTAGCTCAGG     279 bp
  R                                        GCAACTTGATACCAGCAGTGCG                                                                    
  SIM                                      F                               TTGCGGAAGAAGCCCAGCCAG           613 bp                    
  R                                        GCG TCT CCG ATT TCA CTG TGG C                                                             
  NDM                                      F                               CCC GGC CAC ACC AGT GAC A       129 bp                    
  R                                        GTA GTG CTC AGT GTC GGC AT                                                                
  SPM                                      F                               GGG TGG CTA AGA CTA TGA AGC C   447 bp                    
  R                                        GCC GCC GAG CTG AAT CGG                                                                   
  **rmtA, rmtC, rmtD, rmtG, rmtH**         rmtA                            F                               AAACTATTCCGCATGGTTC       88 bp
  R                                        TCATGTACACAAGCTCTTTCC                                                                     
  rmtC                                     F                               CAGGGGTTCCAACAAGT               246 bp                    
  R                                        AGAGTATATAGCTTGAACATAAGTAGA                                                               
  rmtD                                     F                               TCGTTTCAGCACGTAAAACA            652 bp                    
  R                                        CAGCGCGAAATTCAAAAAGG                                                                      
  rmtG                                     F                               ACGGAATGCCGCGCGAAGTA            381 bp                    
  R                                        TCTCCGCAAGCAGATCGCCG                                                                      
  rmtH                                     F                               ATGACCATTGAACAGGCAGC            464 bp                    
  R                                        AGGGCAAAGGTAAAATCCCA                                                                      
  **armA, npmA, rmtB, rmtE, rmtF**         armA                            F                               ATTTTAGATTTTGGTTGTGGC     101 bp
  R                                        ATCTCAGCTCTATCAATATCG                                                                     
  npmA                                     F                               GGGCTATCTAATGTGGTG              229 bp                    
  R                                        TTTTTATTTCCGCTTCTTCGT                                                                     
  rmtB                                     F                               ACTTTTACAATCCCTCAATAC           171 bp                    
  R                                        AAGTATATAAGTTCTGTTCCG                                                                     
  rmtE                                     F                               GATGCCGTGTCTGTTACGCCG           446 bp                    
  R                                        ACGTGAACCCACGAGTCCTGC                                                                     
  rmtF                                     F                               CGATCCTACTGGGCTCCAT             314 bp                    
  R                                        GGCATAGTGCTTTTCCATGC                                                                      

4. Results {#sec210450}
==========

Forty isolates of *K. pneumoniae* were evaluated to determine the existence of and the relationship among carbapenemase, ESBL, and 16S rRNA methyltransferase genes. The strains were isolated from 4 blood, 15 urine, 7 bronchoalveolar lavage, 12 sputum, and 2 surgical wound samples. Twenty *K. pneumoniae* strains were resistant to amikacin, and 40 were resistant to gentamicin. The MIC values of amikacin and gentamicin were found to be \> 512 µg/mL in five isolates and \> 128 µg/mL in 10 isolates, respectively ([Table 2](#tbl53068){ref-type="table"}).

###### Distribution of Amikacin and Gentamicin MIC Values Among the *K. pneumoniae* Isolates

  Amikacin MIC Value, µg/mL   Number of Isolates   Gentamicin MIC Value, µg/mL   Number of Isolates
  --------------------------- -------------------- ----------------------------- --------------------
  **\> 512**                  5                    \> 128                        10
  **128**                     5                    128                           10
  **64**                      5                    64                            4
  **32**                      1                    32                            8
  **16**                      4                    16                            2
  **-**                       \-                   8                             2
  **-**                       \-                   4                             4
  **Total**                   20                   Total                         40

PCR was performed only on five isolates with an MIC value of \> 512 μg/mL for amikacin and \> 128 μg/mL for gentamicin. A specific DNA fragment with a length of 246 bp was amplified on the *rmtC* gene in four isolates with the above-mentioned MIC values. Of these four isolates, three contained the *bla*~*NDM-1*~gene and all were found to have at least one ESBL gene ([Table 3](#tbl53069){ref-type="table"}). A sequence analysis was performed to confirm the PCR results.

###### Co-Existence of ESBL and 16S rRNA Methyltransferase Genes Among the *K. pneumoniae* Isolates (BAL: Bronchoalveolar Lavage)

  Isolates        Amikacin MIC value, µg/mL   Gentamicin MIC Value, µg/mL   16S Rrna Methyltransferase Gene   Carbapenemase Genes   ESBL Genes
  --------------- --------------------------- ----------------------------- --------------------------------- --------------------- ------------
  **1 (Urine)**   \> 512                      \> 128                        rmtC                              NDM-1                 SHV
  **2 (Urine)**   \> 512                      \> 128                        rmtC                              NDM-1, OXA-48         TEM,SHV
  **3 (Blood)**   \> 512                      \> 128                        rmtC                              OXA-48                TEM
  **4 (BAL)**     \> 512                      \> 128                        rmtC                              NDM-1,OXA-48          TEM,SHV
  **5 (BAL)**     \> 512                      \> 128                        \-                                OXA-48                SHV

![rmtC-PCR Products\
Lane 1, 50 bp DNA ladder; lane 4, sample 1; lane 7, sample 2; lane 13, sample 3; lane 16, sample 4 (246 bp); lane 9, negative control.](jjm-09-10-33990-g001){#fig38692}

![NDM-1-PCR Products\
Lane 1, 100 bp DNA ladder; lane 2, negative control, lane 7, sample 1; lane 9, sample 2; lane 11, sample 4 (129 bp); lane 9, negative control.](jjm-09-10-33990-g002){#fig38693}

![TEM and SHV-PCR Products\
Lane 5, 100 bp DNA ladder; lane 4, sample 1; lane 3, sample 2; lane 2, sample 3; lane 1, sample 4 (TEM: 800 bp, SHV: 713 bp).](jjm-09-10-33990-g003){#fig38694}

![OXA-48-PCR Products\
Lane 1, 100 bp DNA ladder; lane 2, sample 2; lane 3, sample 3; lane 4; sample 4; lane 5, sample 5; lane 6, negative control.](jjm-09-10-33990-g004){#fig38695}

5. Discussion {#sec210451}
=============

Combination antibiotic therapy has been shown to have synergistic effects in vitro and in vivo. This treatment alternative is usually preferred in clinics to prevent the development of resistance without requiring a toxic dose or widening the antibacterial spectrum ([@A33990R17]). In particular, carbapenem and aminoglycoside are used in combination prior to colistin and tigecycline in the treatment of infections of *Enterobacteriaceae* isolates that produce carbapenemase. For example, the combinations of meropenem/imipenem and amikacin or doripenem and gentamicin have been suggested as an effective alternative treatment for *K. pneumoniae* strains that produce carbapenemase ([@A33990R18], [@A33990R19]).

In recent years, plasmids that transport ESBL and carbapenemase enzymes have been found to carry 16S rRNA methyltransferase aminoglycoside-resistant genes. Thus, aminoglycoside and beta-lactam antibiotic combinations are no longer considered clinically effective. This finding was verified by Wu et al., who detected the *armA* methyltransferase gene on a plasmid that codes the *K. pneumoniae* carbapenemase enzyme ([@A33990R20]).

Despite having low prevalence in different types of bacteria, the 16S rRNA methyltransferase gene is globally spreading because of the plasmids that transport carbapenemase and ESBL genes among gram-negative bacilli. In Taiwan, the *rmtB* and *armA* genes were identified in *E. coli* and *K. pneumoniae* isolates with a high level of amikacin resistance, and the prevalence of *armA* was found to be higher than that of *rmtB* ([@A33990R7]). In Japan, *rmtA*, *rmtB*, *npmA*, and *armA* were detected in gram-negative isolates with an amikacin MIC value of over 512 mg/L ([@A33990R21]). In Korea, the co-existence of *rmtE* and CMY-2 cephalosporinase was reported ([@A33990R22]). In China, *armA* and *rmtB* genes were found in gram-negative bacteria isolates with the amikacin MIC value being consistently over 512 mg/L ([@A33990R23]).

In Saudi Arabia, the relationship between ESBL and 16S rRNA methyltransferase genes was investigated, and the *rmtB*, *rmtC*, and *armA* genes were detected in the same isolates ([@A33990R24]). Fritsche et al. analyzed gram-negative bacteria isolates from North America, Latin America, and Europe and found that the *armA*, *rmtB*, and *rmtD* genes were resistant to aminoglycosides in isolates with amikacin MIC values of over 128 µg/L ([@A33990R25]). The existence of the *rmtF* methyltransferase gene was reported in Nepal, the United States, India, and England ([@A33990R26]). The *rmtH* gene was determined in a *K. pneumoniae* strain isolated from an American soldier who was wounded in Iraq in 2006 ([@A33990R27]). In Turkey, the *rmtB* gene was shown in a *K. pneumoniae* isolate that was aminoglycoside resistant ([@A33990R28], [@A33990R29]). In another study, 16S rRNA methyltransferase resistance was not found in any of the 59 aminoglycoside-resistant clinical isolates that were evaluated over a five-year period ([@A33990R30]).

In the current study, the *rmtC* gene was detected in four isolates with an MIC value of \> 512 µg/mL for amikacin and \> 128 µg/mL for gentamicin. We determined both NDM-1 and *rmtC* genes in three isolates with a high level of aminoglycoside resistance. We found at least one ESBL gene in all four isolates that contained the *rmtC* gene. The co-existence of the NDM-1 and *rmtC* genes was previously observed in *K. pneumoniae* strains isolated from clinical samples in Australia, Nepal, Kenya, and Bangladesh. However, to the best of our knowledge, this study is the first report conducted in Turkey showing the presence of the *rmtC* gene and the co-existence of NDM-1 and *rmtC* resistance genes among clinical isolates.

The combination of beta-lactam and aminoglycoside is an important treatment alternative for gram-negative bacterial infections, but it has lost its clinical significance because of 16S rRNA methyltransferase and other aminoglycoside-resistant mechanisms. 16S rRNA methyltransferase-type resistance has low prevalence but spreads easily in plasmids that transport beta-lactamase genes such as NDM-1. This resistance can spread across a wide geographic region in Turkey and in other parts of the world. Further studies are needed to determine the mechanisms of 16S rRNA methyltransferase and carbapenemase resistance. The spread of these types of resistances should be monitored using molecular analyses.
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